Spinal manipulative therapy vs inert interventions
Serious adverse events · Patients with acute low‐back pain
1 finding from 1 review
- no estimate extracted2 studies · 2 participantsGRADE not reported
Findings
What do systematic reviews say?
65 questions · 65 findings · 30 reviews
No studies found 9 · 13.8%GRADE not reported 5 · 7.7%Very low 8 · 12.3%Low 13 · 20%Moderate 23 · 35.4%High 7 · 10.8%
Spinal manipulative therapy vs other interventions
Serious adverse events · Patients with acute low‐back pain
1 finding from 1 review
- no estimate extracted2 studies · 2 participantsGRADE not reported
Spinal manipulative therapy vs sham SMT
Serious adverse events · Patients with acute low‐back pain
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
Spinal manipulative therapy plus another intervention vs the intervention alone
Serious adverse events · Patients with acute low‐back pain
1 finding from 1 review
- no estimate extracted2 studies · 2 participantsGRADE not reported
Intervention not reported
Number of serious adverse events ‐ pulmonary · treating infections in people with neutropenia or neutrophil dysfunction
It is very uncertain whether the intervention changes number of serious adverse events ‐ pulmonary (very low certainty).
1 finding from 1 review
- Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction 2016 · Cochrane Headline outcomes onlyRR 0.85 [0.38, 1.88]1 study · 24 participantsVery low
Early physical therapy vs control
Serious adverse events ‐ in total population randomised · critically ill patients
Early physical therapy showed no clear difference in serious adverse events ‐ in total population randomised compared with control (moderate certainty).
1 finding from 1 review
- Interventions for preventing critical illness polyneuropathy and critical illness myopathy 2014 · Cochrane Headline outcomes onlyRR 3.36 [0.14, 80.62]1 study · 104 participantsModerate
Intensive insulin therapy vs conventional insulin therapy
Serious adverse events, ‐ in total population randomised ‐ hypoglycaemia · critically ill patients
Intensive insulin therapy leads to higher serious adverse events, ‐ in total population randomised ‐… compared with conventional insulin therapy (high certainty).
1 finding from 1 review
- Interventions for preventing critical illness polyneuropathy and critical illness myopathy 2014 · Cochrane Headline outcomes onlyRR 6.27 [4.15, 9.49]2 studies · 2748 participantsHigh
PPI plus usual care vs usual care alone or chronic obstructive pulmonary disease
Pneumonia and other serious adverse events · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
- Proton pump inhibitors for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Exercise vs control
Serious adverse events · people with pulmonary hypertension
Exercise showed no clear difference in serious adverse events compared with control (moderate certainty).
1 finding from 1 review
- Exercise‐based rehabilitation programmes for pulmonary hypertension 2023 · Cochrane Headline outcomes onlyRD 011 studies · 439 participantsModerate
Linezolid vs no linezolid
Serious adverse events · drug‐resistant pulmonary tuberculosis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen
Serious adverse events · adults with drug‐sensitive pulmonary tuberculosis
Gatifloxacin‐containing 4‐month ATT regimens showed no clear difference in serious adverse events compared with standard 6‐month ATT regimens (moderate certainty).
1 finding from 1 review
- Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis 2019 · Cochrane Headline outcomes onlyRR 1.02 [0.58, 1.77]2 studies · 1993 participantsModerate
Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen
Serious adverse events · adults with drug‐sensitive pulmonary tuberculosis
Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in serious adverse events compared with standard 6‐month ATT regimen (moderate certainty).
1 finding from 1 review
- Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis 2019 · Cochrane Headline outcomes onlyRR 0.97 [0.74, 1.27]4 studies · 3548 participantsModerate
Intervention not reported
Serious adverse events · treating pulmonary TB
The intervention showed no clear difference in serious adverse events (moderate certainty).
1 finding from 1 review
- Fixed‐dose combinations of drugs versus single‐drug formulations for treating pulmonary tuberculosis 2016 · Cochrane Headline outcomes onlyRR 1.45 [0.9, 2.33]6 studies · 3388 participantsModerate
Fixed‐dose combination aclidinium/formoterol vs placebo
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes onlyOR 1.12 [0.72, 1.74]4 studies · 2527 participantsModerate
Umeclidinium bromide vs placebo
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Umeclidinium bromide showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) 2017 · Cochrane Headline outcomes onlyOR 1.33 [0.89, 2]4 studies · 1922 participantsModerate
Tiotropium vs ipratropium
All‐cause serious adverse events · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium leads to lower all‐cause serious adverse events compared with ipratropium (high certainty).
1 finding from 1 review
- Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease 2015 · Cochrane Headline outcomes onlyOR 0.5 [0.34, 0.73]2 studies · 1073 participantsHigh
Aclidinium bromide vs tiotropium
Non‐fatal serious adverse events · patients with stable chronic obstructive pulmonary disease
It is very uncertain whether aclidinium bromide changes non‐fatal serious adverse events compared with tiotropium (very low certainty).
1 finding from 1 review
- Aclidinium bromide for stable chronic obstructive pulmonary disease 2014 · Cochrane Headline outcomes onlyOR 0.67 [0.17, 2.65]2 studies · 729 participantsVery low
Aclidinium bromide vs placebo
Non‐fatal serious adverse events · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- Aclidinium bromide for stable chronic obstructive pulmonary disease 2014 · Cochrane Headline outcomes onlyOR 0.89 [0.7, 1.14]10 studies · 5651 participantsModerate
Tiotropium + LABA/ICS combination vs tiotropium
Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease
Tiotropium + LABA/ICS combination showed no clear difference in serious adverse events (non‐fatal) compared with tiotropium (low certainty).
1 finding from 1 review
- Combination inhaled steroid and long‐acting beta₂‐agonist in addition to tiotropium versus tiotropium or combination… 2016 · Cochrane Headline outcomes onlyOR 0.86 [0.57, 1.3]4 studies · 1758 participantsLow
Indacaterol vs long‐acting beta2‐agonist alone
Serious adverse events Adverse events · patients with chronic obstructive pulmonary disease
Indacaterol showed no clear difference in serious adverse events Adverse events compared with twice‐daily long‐acting beta2‐agonists (moderate certainty).
1 finding from 1 review
- Indacaterol, a once‐daily beta₂‐agonist, versus twice‐daily beta₂‐agonists or placebo for chronic obstructive… 2015 · Cochrane Headline outcomes onlyOR 1.02 [0.79, 1.32]4 studies · 3266 participantsModerate